Clinical Trial

Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

Name: Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection. — clinical trial record (NCT06982534)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.

Trial Details

NCT Number	NCT06982534
Lead Sponsor	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions	Systemic Sclerosis (SSc)
Enrollment	24 participants
Start Date	2025-06
Primary Completion	2027-12 (estimated)
Study Completion	2040-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-21